Gyre Therapeutics, Inc. GYRE Payments to Acquire Equity Method Investments
Payments to Acquire Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireEquityMethodInvestments.
The official record: Gyre Therapeutics, Inc.’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s payments to acquire equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s payments to acquire equity method investments?
- Gyre Therapeutics, Inc. (GYRE) reported payments to acquire equity method investments of $421.5K in Q4 2024.
- How has Gyre Therapeutics, Inc.'s payments to acquire equity method investments changed year-over-year?
- Gyre Therapeutics, Inc.'s payments to acquire equity method investments increased by 68.6% year-over-year, from $250K to $421.5K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s payments to acquire equity method investments?
- Over 2 years (2022 to 2024), Gyre Therapeutics, Inc.'s payments to acquire equity method investments has grown at a 12.5% compound annual growth rate (CAGR), from $1.33M to $1.69M.